Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
A Randomized, Observer-blind, Placebo-controlled, Two-part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo
Sponsor: Janssen Vaccines & Prevention B.V.
A PHASE2 clinical study on Hemorrhagic Fever, Ebola, this trial is completed. The trial is conducted by Janssen Vaccines & Prevention B.V. and has accumulated 19 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
19 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE2
▶ Show 14 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Nov 2019 — Jan 2020 [monthly]
Completed PHASE2
-
May 2019 — Nov 2019 [monthly]
Completed PHASE2
-
Mar 2019 — May 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2017 — Mar 2018 [monthly]
Recruiting PHASE2
-
Apr 2017 — Jul 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Vaccines & Prevention B.V.
- Walter Reed Army Institute of Research (WRAIR)
For direct contact, visit the study record on ClinicalTrials.gov .